Personalized treatment option for HR+/HER2- breast cancer patients

July 14, 2025

A current clinical trial at Roswell Park Comprehensive Cancer Center is revealing why certain patients with metastatic HR+/HER2- breast cancer do not respond to cyclin-dependent kinase (CDK) 4/6 inhibitors as well as others.

Key findings:

·       Certain factors may influence progression-free survival (PFS) in these patient populations.

·       Cyclin A and E expression “was significantly higher in the tumors of patients with shorter PFS” before being treated with CDK 4/6 inhibitors. The researchers attributed this to the “buildup of macrophages.”

·       In patients with long PFS, “gene enrichment for immune cell activation emerged during therapy, along with a reduction in cell cycle gene expression.”

The authors hope their study aids precision medicine for these patients.

About the Author

Erin Brady

Managing Editor

Erin Brady is Managing Editor of Medical Laboratory Observer.

Sign up for Medical Laboratory Observer eNewsletters